What Happened in This Case

An illustrative patient profile — a retired engineer in his mid-60s with adjacent segment disease at L3-L4 five years after an L4-L5 lumbar fusion — chose intra-annular fibrin injection over revision fusion and reduced pain from 7/10 to 2/10 within six months. This composite case covers baseline presentation, clinical approach, recovery course, and key trade-offs.

Note: This is a composite illustrative scenario drawn from patterns common to post-fusion patients seen in this clinical setting. It is not a report on a specific, identifiable individual. Individual outcomes vary.

At a Glance: Case Summary

What Is Adjacent Segment Disease, and Why Does It Bring Patients Back?

Adjacent segment disease (ASD) is the development of new, symptomatic disc degeneration at the spinal level immediately above or below a prior fusion. Because the fused segment no longer moves, biomechanical load transfers to neighboring discs — accelerating wear on structures that were not the original problem. For a full explanation, see What Is Adjacent Segment Disease? The Hidden Risk of Spinal Fusion.

ASD is one of the most common reasons fusion patients return to a spine clinic. Back surgery carries roughly a 40% failure rate under the broader category of failed back surgery syndrome, and revision surgery rates can exceed 20% within 10 years. Understanding this context matters for patients evaluating their next step.

What Was the Patient’s Starting Point?

This patient presented after years of escalating low back pain. His original L4-L5 fusion delivered approximately 18 to 24 months of meaningful relief before pain returned — this time one level above the fused segment. At evaluation, he reported daily pain at 7/10, worsening with standing, walking, and prolonged sitting. He had stopped woodworking, shortened his daily walks, and was sleeping poorly.

Imaging confirmed advanced degenerative changes at L3-L4 with multiple annular tears and disc-height collapse. L5-S1 showed early degeneration but was not symptomatic. The clinical picture was a textbook presentation of ASD: load that previously distributed across the L4-L5 motion segment was now concentrated at L3-L4.

Prior conservative care was extensive and well-documented: multiple physical therapy courses, six epidural steroid injections over two years, NSAIDs, gabapentin, chiropractic care, and acupuncture. Each modality offered short-lived relief without changing the underlying disc pathology — a pattern consistent with the AAFP systematic review finding that epidural steroid injections are not effective for chronic low back pain as a standalone intervention.

The surgical recommendation received elsewhere was revision fusion at L3-L4 — carrying a 3-to-6-month recovery, the same biomechanical risk of shifting degeneration up to L2-L3, and no certainty of improvement. For patients weighing what options actually exist, see How to Evaluate Spine Repair Options After Surgery.

Why Was Intra-Annular Fibrin Injection Selected?

The clinical team selected intra-annular fibrin injection — a biologic disc repair technique that uses an FDA-approved fibrin sealant to close annular tears and provide a scaffold for the disc’s natural healing response. The decision rested on four factors.

• Confirmed pain generator. Provocative discography reproduced the patient’s typical pain at L3-L4 and demonstrated contrast extravasation through annular tears, identifying the disc as the source.
• Motion preservation. Fusing L3-L4 above an existing L4-L5 fusion would create a two-level rigid construct, increasing load on L2-L3 and raising the risk of a third-level ASD cascade.
• Published outcome data. Long-term follow-up data on the fibrin procedure report VAS pain scores improving from 72.4 mm at baseline to 33.0 mm at 104 weeks, with 70% patient satisfaction at two-year follow-up. Among patients with failed prior spine surgery specifically, 80% reported positive outcomes — individual outcomes vary.
• Sequencing logic. If the fibrin procedure did not produce sufficient relief, revision fusion remained available. The reverse is not true: a failed revision fusion would have foreclosed the biologic repair option.

The patient and his spouse were walked through the full risk profile, including the realistic healing timeline (improvement unfolds over 6 to 12 months, not days) and the possibility that the procedure might not eliminate all pain. He elected to proceed. For patients earlier in this decision process, see What Is Failed Back Surgery Syndrome? Causes, Symptoms, and Recovery Options and 80% Pain Reduction After Failed Fusion: How a Retired Construction Worker Recovered with Intra-Annular Fibrin Injection.

What Did the Procedure Involve?

The fibrin procedure was performed under imaging guidance using a thin catheter inserted through the skin — no incisions, under one hour, with local anesthesia and light sedation. An FDA-approved fibrin sealant was delivered directly into the affected disc at L3-L4 to seal the identified annular tears. The fibrin sealant used is FDA-approved as a sealant; specific clinical applications, candidacy, and outcomes vary by patient.

The patient was discharged the same day with a structured activity protocol and follow-up schedule. He was advised that the biological healing process takes time and that early activity restrictions would protect the repair while the disc responded.

How Did Recovery Progress?

Recovery followed a pattern consistent with published fibrin outcome data, with improvement unfolding gradually over weeks and months rather than immediately.

• Weeks 1–4: Activity was restricted to gentle walking. The patient reported modest initial reduction in baseline pain but noted soreness at the injection site. Sleep improved slightly.
• Weeks 5–12: Pain scores began declining more noticeably. The patient resumed light activity, including short woodworking sessions, without the severe exacerbations he had experienced before the procedure.
• Months 3–6: Pain stabilized at approximately 2/10, a reduction from the 7/10 baseline. Daily walks extended to 45 minutes. The patient reported returning to activities he had abandoned for more than two years.

At six months, VAS scoring placed him at approximately 22 mm — a reduction from 72 mm at baseline, consistent with the published 72.4-to-33.0 mm trajectory seen in long-term fibrin cohort data. Individual outcomes vary.

What Trade-Offs Did This Case Involve?

The fibrin procedure is not a guaranteed fix, and this case reflects that honestly.

• Incomplete pain elimination. The patient retained mild residual discomfort at 2/10. This aligned with published outcome data showing meaningful improvement — not zero pain — as the realistic benchmark for most patients.
• Time to benefit. Six months is a long time to wait. Patients who need rapid functional return (e.g., physical job requirements) should discuss this timeline in a clinical evaluation.
• L5-S1 monitoring. Early degeneration at L5-S1 was observed at baseline but was not symptomatic. That level will require ongoing monitoring.
• Not every ASD patient is a candidate. Advanced disc-height collapse, absent endplate integrity, or primarily facet-driven pain at the adjacent level would change the clinical calculus. A clinical evaluation is the only way to determine whether the fibrin procedure applies to a specific patient’s anatomy and history.

For a broader look at what the evaluation process involves, see How to Evaluate Regenerative Spine Care After Failed Surgery and Back Pain After Surgery: Regenerative Care FAQs.

How Does This Case Connect to the Broader Failed Surgery Population?

Adjacent segment disease is one subset of a larger group of patients who have had spine surgery and continue to experience pain. The clinical patterns — exhausted conservative care, reluctance to accept another surgery, degenerative changes at adjacent levels — appear repeatedly. Published data across this population show that among patients with failed prior spine surgery, 80% reported positive outcomes with the fibrin procedure; individual outcomes vary.

For additional context on this patient population, see From Failed Back Surgery to Lasting Sciatica Relief and How to Find Lasting Relief for Post-Surgical Pain.

Is the Fibrin Procedure Right for Post-Fusion Patients?

A clinical evaluation is the only way to know for certain. Candidacy depends on the specific pattern of disc pathology, the integrity of the endplates, the number of levels involved, and the patient’s overall clinical history. Not every post-fusion patient with adjacent level pain is a candidate — and not every patient who is a candidate will achieve the same outcome.

For patients who have questions before scheduling a consultation, see FAQ: Regenerative Spine Care After Prior Surgery and Still Have Back Pain After Surgery? FAQ.

Frequently Asked Questions

What is adjacent segment disease?

Adjacent segment disease is the development of symptomatic disc degeneration at the spinal level immediately above or below a prior fusion. Because the fused segment no longer moves, biomechanical load shifts to neighboring discs, accelerating their wear. It is one of the most common reasons fusion patients return to a spine clinic.

Can intra-annular fibrin injection treat adjacent segment disease?

For patients with discogenic pain at the adjacent level confirmed by diagnostic imaging and intact endplates, the fibrin procedure is a motion-preserving option. A clinical evaluation is the only way to determine whether a specific patient’s anatomy and history make them a candidate. Not all adjacent segment disease presentations are appropriate for the fibrin procedure.

How long does recovery from the fibrin procedure take?

Healing unfolds over 6 to 12 months, not days or weeks. Early activity restrictions protect the repair while the disc responds biologically. Patients typically begin noticing meaningful pain reduction within 3 to 6 months; individual timelines vary. A clinical evaluation will provide a more specific recovery framework based on the patient’s case.

What does the published outcome data show for post-fusion patients?

Among patients with failed prior spine surgery, 80% reported positive outcomes with the fibrin procedure in outcome registry data. Across the broader fibrin patient population, the most-tracked cohort — over 7,000 procedures with long-term follow-up — shows an 83% success rate, with VAS pain scores declining from 72.4 mm at baseline to 33.0 mm at 104 weeks. Individual outcomes vary.

Does the fibrin procedure eliminate the option of revision fusion later?

The fibrin procedure does not foreclose revision fusion. If the fibrin procedure does not produce sufficient relief, revision surgery remains available. The reverse is generally not true: a failed revision fusion would likely eliminate the fibrin procedure as a viable next step for that level. This sequencing consideration is one factor the clinical team weighs in recommending a course of treatment.

How is the fibrin procedure performed?

The fibrin procedure is performed under imaging guidance using a thin catheter inserted through the skin — no incisions, under one hour, with local anesthesia and light sedation. An FDA-approved fibrin sealant is delivered directly into the affected disc. The fibrin sealant is FDA-approved as a sealant; specific clinical applications, candidacy, and outcomes vary by patient.

How do I know if I am a candidate?

A clinical evaluation is the only way to know for certain. Candidacy depends on the pattern of disc pathology, endplate integrity, the number of levels involved, and the patient’s overall clinical and surgical history. Schedule a consultation to discuss whether the procedure is right for your situation.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified physician. Treatment decisions depend on your individual medical history and clinical findings. Schedule a consultation to discuss whether the procedure is right for you.